Outcome of patients with primary glioblastoma in Chile: single centre series

Abstract

Background: Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumour. The standard of care is surgical resection, followed by radiotherapy with concurrent and adjuvant temozolomide. In Latin America, there is scarcity of information about the incidence of GBM and even less data regarding outcomes. In this study, we describe the clinicopathologic features, management and outcomes of GBM patients. Methods: We describe a single-centre multidisciplinary team experience in managing GBM patients over an 11-year period (Jan 2005 to Dec 2016). Pathology was reviewed by the pathology collaborator and retrospective chart review performed for treatment and clinical outcomes. Results: We identified 74 patients (50 males) with diagnosis of GBM. Median age at diagnosis was 58 years (range 24-79 years), and median Karnofsky performance status was 80%. Forty-three (58.1%) went to gross total resection, 20 (27%) partial resection and 11 (14.9%) biopsy. Sixty-four (87%) patients received Stupp regimen. The median overall survival (OS) was 13.9 months (standard error (SE) 1.71; 95% confidence interval (CI), 10.56-17.23). In patients treated according to Stupp regimen, the progression-free survival (PFS) was 10 months (

Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis

“…For instance, there needs to be more epidemiologic information. Most of the articles we found were from Brazil [12,18,23,24] and from Mexico [13,14,17,20,25,26] .We found some from Colombia [22], Argentina [27,28], and Chile [19,21]. Nonetheless, most Latin American countries still need to report their epidemiologic information on gliomas.…”

“…The Latino mean age of diagnosis found in this study was 6.1 years lower, for a mean age of 50.89 years, 95% CI (47.8-53.9), suggesting that gliomas occur considerably earlier in Latinos than in non-Hispanic whites and is crucial because it represents a health problem and an economic problem since it is affecting an economically active population [6,15]. Wegman-Ostrosky et al proposed three possible explanations for the younger age at diagnosis [17]: 1) differences in the Latin American population pyramid compared to those from the US, 2) environmental exposure, and 3) genetic factors, such as germline mutations in TP53, MSH2, MLH1, and MSH6 [18,19] Moreover, the reported incidence of glioblastoma increases signi cantly with age, with a median of 63 years. As stated in the CBTRUS, the median age varies by ethnicity, with non-Hispanic whites having a higher median age (64 years) than Hispanics (60 years) [15].…”

“…Only one of the articles used the 2021 WHO classi cation [28]. In addition, even though many of the articles were published after 2016, only one [19] used the 2016 WHO classi cation of CNS tumors. The rest used the 2007 WHO CNS tumors classi cation or the St. Anne-Mayo grading system.…”

The Descriptive and Analytical Epidemiology of Glioblastoma Worldwide: an Informative Science Review

“…Another Brazilian study showed that GB was the most common glioma in patients [52]. In Chile, a 2021 single-center study with 74 patients showed a median OS of 13.9 months [77].…”